Global Krabbe Disease Treatment Market

Krabbe Disease Treatment Comprehensive Study by Type (Infantile (occurs in babies less than six months of age), Late-onset (can happen at any other time)), Diagnosed Test (Imaging Scans (MRI), Nerve Conduction Studies, Eye Examination, Genetic Testing, Amniocentesis), Symptoms (Frequent Vomiting, Feeding Difficulties, Fever, Muscle Spasms, Others) Players and Region - Global Market Outlook to 2030

Krabbe Disease Treatment Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Krabbe Disease Treatment
Krabbe disease is an autosomal recessive genetic disorder. Krabbe disease is an uncommon inherited nerve system ailment that usually leads to death. Krabbe disease is caused by a lack of galactosylceramidase, which causes severe degradation of the myelin sheaths that encase nerves in the brain. Krabbe illness affects 85 to 90 percent of children under the age of six months, but it can also strike later in life. A genetic mutation, or a permanent change in the DNA sequence that makes up a gene, causes Krabbe disease. The product for which the gene codes is affected by the mutation.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Krabbe Disease Treatment market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Polpharma (Poland), Sanofi S.A. (France), Takeda Pharmaceutical Company Limited (Japan), Teva Pharmaceutical Industries Ltd., (Israel), UCB Pharmaceuticals (Belgium), Zhejiang Jiuzhou Pharmaceuticals Co Ltd (China), Abbott Laboratories (United States), GlaxoSmithKline Plc (United Kingdom), Novartis AG (Switzerland) and Johnson & Johnson Services Inc (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Pfizer (United States).

Segmentation Overview
AMA Research has segmented the market of Global Krabbe Disease Treatment market by Type (Infantile (occurs in babies less than six months of age) and Late-onset (can happen at any other time)) and Region.



On the basis of geography, the market of Krabbe Disease Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Diagnosed Test, the sub-segment i.e. Imaging Scans (MRI) will boost the Krabbe Disease Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Symptoms, the sub-segment i.e. Frequent Vomiting will boost the Krabbe Disease Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Emergence of Pharmacological Chaperone Therapy

Market Growth Drivers:
Increase in Clinical Development of the Treatment for the Krabbe Disease and Highly Developed Technologies and Innovative Drugs for Management of Krabbe Disease

Challenges:
Limited Patient Pool for Clinical Trial

Restraints:
High Cost Associated with Treatment

Opportunities:
Rise in Investment in R & D

Market Leaders and their expansionary development strategies
In 2021, Pfizer announced that it had entered into a definitive agreement to acquire Arena Pharmaceuticals, a clinical stage company specializing in therapies treating immuno-inflammatory diseases, for USD 6.7 billion dollars.



Key Target Audience
Venture Capitalists and Private Equity Firms, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Infantile (occurs in babies less than six months of age)
  • Late-onset (can happen at any other time)
By Diagnosed Test
  • Imaging Scans (MRI)
  • Nerve Conduction Studies
  • Eye Examination
  • Genetic Testing
  • Amniocentesis

By Symptoms
  • Frequent Vomiting
  • Feeding Difficulties
  • Fever
  • Muscle Spasms
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in Clinical Development of the Treatment for the Krabbe Disease
      • 3.2.2. Highly Developed Technologies and Innovative Drugs for Management of Krabbe Disease
    • 3.3. Market Challenges
      • 3.3.1. Limited Patient Pool for Clinical Trial
    • 3.4. Market Trends
      • 3.4.1. Emergence of Pharmacological Chaperone Therapy
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Krabbe Disease Treatment, by Type, Diagnosed Test, Symptoms and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Krabbe Disease Treatment (Value)
      • 5.2.1. Global Krabbe Disease Treatment by: Type (Value)
        • 5.2.1.1. Infantile (occurs in babies less than six months of age)
        • 5.2.1.2. Late-onset (can happen at any other time)
      • 5.2.2. Global Krabbe Disease Treatment by: Diagnosed Test (Value)
        • 5.2.2.1. Imaging Scans (MRI)
        • 5.2.2.2. Nerve Conduction Studies
        • 5.2.2.3. Eye Examination
        • 5.2.2.4. Genetic Testing
        • 5.2.2.5. Amniocentesis
      • 5.2.3. Global Krabbe Disease Treatment by: Symptoms (Value)
        • 5.2.3.1. Frequent Vomiting
        • 5.2.3.2. Feeding Difficulties
        • 5.2.3.3. Fever
        • 5.2.3.4. Muscle Spasms
        • 5.2.3.5. Others
      • 5.2.4. Global Krabbe Disease Treatment Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Krabbe Disease Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Polpharma (Poland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sanofi S.A. (France)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Takeda Pharmaceutical Company Limited (Japan)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Teva Pharmaceutical Industries Ltd., (Israel)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. UCB Pharmaceuticals (Belgium)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Zhejiang Jiuzhou Pharmaceuticals Co Ltd (China)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Abbott Laboratories (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. GlaxoSmithKline Plc (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Novartis AG (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Johnson & Johnson Services Inc (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Krabbe Disease Treatment Sale, by Type, Diagnosed Test, Symptoms and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Krabbe Disease Treatment (Value)
      • 7.2.1. Global Krabbe Disease Treatment by: Type (Value)
        • 7.2.1.1. Infantile (occurs in babies less than six months of age)
        • 7.2.1.2. Late-onset (can happen at any other time)
      • 7.2.2. Global Krabbe Disease Treatment by: Diagnosed Test (Value)
        • 7.2.2.1. Imaging Scans (MRI)
        • 7.2.2.2. Nerve Conduction Studies
        • 7.2.2.3. Eye Examination
        • 7.2.2.4. Genetic Testing
        • 7.2.2.5. Amniocentesis
      • 7.2.3. Global Krabbe Disease Treatment by: Symptoms (Value)
        • 7.2.3.1. Frequent Vomiting
        • 7.2.3.2. Feeding Difficulties
        • 7.2.3.3. Fever
        • 7.2.3.4. Muscle Spasms
        • 7.2.3.5. Others
      • 7.2.4. Global Krabbe Disease Treatment Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Krabbe Disease Treatment: by Type(USD Million)
  • Table 2. Krabbe Disease Treatment Infantile (occurs in babies less than six months of age) , by Region USD Million (2018-2023)
  • Table 3. Krabbe Disease Treatment Late-onset (can happen at any other time) , by Region USD Million (2018-2023)
  • Table 4. Krabbe Disease Treatment: by Diagnosed Test(USD Million)
  • Table 5. Krabbe Disease Treatment Imaging Scans (MRI) , by Region USD Million (2018-2023)
  • Table 6. Krabbe Disease Treatment Nerve Conduction Studies , by Region USD Million (2018-2023)
  • Table 7. Krabbe Disease Treatment Eye Examination , by Region USD Million (2018-2023)
  • Table 8. Krabbe Disease Treatment Genetic Testing , by Region USD Million (2018-2023)
  • Table 9. Krabbe Disease Treatment Amniocentesis , by Region USD Million (2018-2023)
  • Table 10. Krabbe Disease Treatment: by Symptoms(USD Million)
  • Table 11. Krabbe Disease Treatment Frequent Vomiting , by Region USD Million (2018-2023)
  • Table 12. Krabbe Disease Treatment Feeding Difficulties , by Region USD Million (2018-2023)
  • Table 13. Krabbe Disease Treatment Fever , by Region USD Million (2018-2023)
  • Table 14. Krabbe Disease Treatment Muscle Spasms , by Region USD Million (2018-2023)
  • Table 15. Krabbe Disease Treatment Others , by Region USD Million (2018-2023)
  • Table 16. South America Krabbe Disease Treatment, by Country USD Million (2018-2023)
  • Table 17. South America Krabbe Disease Treatment, by Type USD Million (2018-2023)
  • Table 18. South America Krabbe Disease Treatment, by Diagnosed Test USD Million (2018-2023)
  • Table 19. South America Krabbe Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 20. Brazil Krabbe Disease Treatment, by Type USD Million (2018-2023)
  • Table 21. Brazil Krabbe Disease Treatment, by Diagnosed Test USD Million (2018-2023)
  • Table 22. Brazil Krabbe Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 23. Argentina Krabbe Disease Treatment, by Type USD Million (2018-2023)
  • Table 24. Argentina Krabbe Disease Treatment, by Diagnosed Test USD Million (2018-2023)
  • Table 25. Argentina Krabbe Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 26. Rest of South America Krabbe Disease Treatment, by Type USD Million (2018-2023)
  • Table 27. Rest of South America Krabbe Disease Treatment, by Diagnosed Test USD Million (2018-2023)
  • Table 28. Rest of South America Krabbe Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 29. Asia Pacific Krabbe Disease Treatment, by Country USD Million (2018-2023)
  • Table 30. Asia Pacific Krabbe Disease Treatment, by Type USD Million (2018-2023)
  • Table 31. Asia Pacific Krabbe Disease Treatment, by Diagnosed Test USD Million (2018-2023)
  • Table 32. Asia Pacific Krabbe Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 33. China Krabbe Disease Treatment, by Type USD Million (2018-2023)
  • Table 34. China Krabbe Disease Treatment, by Diagnosed Test USD Million (2018-2023)
  • Table 35. China Krabbe Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 36. Japan Krabbe Disease Treatment, by Type USD Million (2018-2023)
  • Table 37. Japan Krabbe Disease Treatment, by Diagnosed Test USD Million (2018-2023)
  • Table 38. Japan Krabbe Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 39. India Krabbe Disease Treatment, by Type USD Million (2018-2023)
  • Table 40. India Krabbe Disease Treatment, by Diagnosed Test USD Million (2018-2023)
  • Table 41. India Krabbe Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 42. South Korea Krabbe Disease Treatment, by Type USD Million (2018-2023)
  • Table 43. South Korea Krabbe Disease Treatment, by Diagnosed Test USD Million (2018-2023)
  • Table 44. South Korea Krabbe Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 45. Taiwan Krabbe Disease Treatment, by Type USD Million (2018-2023)
  • Table 46. Taiwan Krabbe Disease Treatment, by Diagnosed Test USD Million (2018-2023)
  • Table 47. Taiwan Krabbe Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 48. Australia Krabbe Disease Treatment, by Type USD Million (2018-2023)
  • Table 49. Australia Krabbe Disease Treatment, by Diagnosed Test USD Million (2018-2023)
  • Table 50. Australia Krabbe Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific Krabbe Disease Treatment, by Type USD Million (2018-2023)
  • Table 52. Rest of Asia-Pacific Krabbe Disease Treatment, by Diagnosed Test USD Million (2018-2023)
  • Table 53. Rest of Asia-Pacific Krabbe Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 54. Europe Krabbe Disease Treatment, by Country USD Million (2018-2023)
  • Table 55. Europe Krabbe Disease Treatment, by Type USD Million (2018-2023)
  • Table 56. Europe Krabbe Disease Treatment, by Diagnosed Test USD Million (2018-2023)
  • Table 57. Europe Krabbe Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 58. Germany Krabbe Disease Treatment, by Type USD Million (2018-2023)
  • Table 59. Germany Krabbe Disease Treatment, by Diagnosed Test USD Million (2018-2023)
  • Table 60. Germany Krabbe Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 61. France Krabbe Disease Treatment, by Type USD Million (2018-2023)
  • Table 62. France Krabbe Disease Treatment, by Diagnosed Test USD Million (2018-2023)
  • Table 63. France Krabbe Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 64. Italy Krabbe Disease Treatment, by Type USD Million (2018-2023)
  • Table 65. Italy Krabbe Disease Treatment, by Diagnosed Test USD Million (2018-2023)
  • Table 66. Italy Krabbe Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 67. United Kingdom Krabbe Disease Treatment, by Type USD Million (2018-2023)
  • Table 68. United Kingdom Krabbe Disease Treatment, by Diagnosed Test USD Million (2018-2023)
  • Table 69. United Kingdom Krabbe Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 70. Netherlands Krabbe Disease Treatment, by Type USD Million (2018-2023)
  • Table 71. Netherlands Krabbe Disease Treatment, by Diagnosed Test USD Million (2018-2023)
  • Table 72. Netherlands Krabbe Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 73. Rest of Europe Krabbe Disease Treatment, by Type USD Million (2018-2023)
  • Table 74. Rest of Europe Krabbe Disease Treatment, by Diagnosed Test USD Million (2018-2023)
  • Table 75. Rest of Europe Krabbe Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 76. MEA Krabbe Disease Treatment, by Country USD Million (2018-2023)
  • Table 77. MEA Krabbe Disease Treatment, by Type USD Million (2018-2023)
  • Table 78. MEA Krabbe Disease Treatment, by Diagnosed Test USD Million (2018-2023)
  • Table 79. MEA Krabbe Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 80. Middle East Krabbe Disease Treatment, by Type USD Million (2018-2023)
  • Table 81. Middle East Krabbe Disease Treatment, by Diagnosed Test USD Million (2018-2023)
  • Table 82. Middle East Krabbe Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 83. Africa Krabbe Disease Treatment, by Type USD Million (2018-2023)
  • Table 84. Africa Krabbe Disease Treatment, by Diagnosed Test USD Million (2018-2023)
  • Table 85. Africa Krabbe Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 86. North America Krabbe Disease Treatment, by Country USD Million (2018-2023)
  • Table 87. North America Krabbe Disease Treatment, by Type USD Million (2018-2023)
  • Table 88. North America Krabbe Disease Treatment, by Diagnosed Test USD Million (2018-2023)
  • Table 89. North America Krabbe Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 90. United States Krabbe Disease Treatment, by Type USD Million (2018-2023)
  • Table 91. United States Krabbe Disease Treatment, by Diagnosed Test USD Million (2018-2023)
  • Table 92. United States Krabbe Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 93. Canada Krabbe Disease Treatment, by Type USD Million (2018-2023)
  • Table 94. Canada Krabbe Disease Treatment, by Diagnosed Test USD Million (2018-2023)
  • Table 95. Canada Krabbe Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 96. Mexico Krabbe Disease Treatment, by Type USD Million (2018-2023)
  • Table 97. Mexico Krabbe Disease Treatment, by Diagnosed Test USD Million (2018-2023)
  • Table 98. Mexico Krabbe Disease Treatment, by Symptoms USD Million (2018-2023)
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Krabbe Disease Treatment: by Type(USD Million)
  • Table 110. Krabbe Disease Treatment Infantile (occurs in babies less than six months of age) , by Region USD Million (2025-2030)
  • Table 111. Krabbe Disease Treatment Late-onset (can happen at any other time) , by Region USD Million (2025-2030)
  • Table 112. Krabbe Disease Treatment: by Diagnosed Test(USD Million)
  • Table 113. Krabbe Disease Treatment Imaging Scans (MRI) , by Region USD Million (2025-2030)
  • Table 114. Krabbe Disease Treatment Nerve Conduction Studies , by Region USD Million (2025-2030)
  • Table 115. Krabbe Disease Treatment Eye Examination , by Region USD Million (2025-2030)
  • Table 116. Krabbe Disease Treatment Genetic Testing , by Region USD Million (2025-2030)
  • Table 117. Krabbe Disease Treatment Amniocentesis , by Region USD Million (2025-2030)
  • Table 118. Krabbe Disease Treatment: by Symptoms(USD Million)
  • Table 119. Krabbe Disease Treatment Frequent Vomiting , by Region USD Million (2025-2030)
  • Table 120. Krabbe Disease Treatment Feeding Difficulties , by Region USD Million (2025-2030)
  • Table 121. Krabbe Disease Treatment Fever , by Region USD Million (2025-2030)
  • Table 122. Krabbe Disease Treatment Muscle Spasms , by Region USD Million (2025-2030)
  • Table 123. Krabbe Disease Treatment Others , by Region USD Million (2025-2030)
  • Table 124. South America Krabbe Disease Treatment, by Country USD Million (2025-2030)
  • Table 125. South America Krabbe Disease Treatment, by Type USD Million (2025-2030)
  • Table 126. South America Krabbe Disease Treatment, by Diagnosed Test USD Million (2025-2030)
  • Table 127. South America Krabbe Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 128. Brazil Krabbe Disease Treatment, by Type USD Million (2025-2030)
  • Table 129. Brazil Krabbe Disease Treatment, by Diagnosed Test USD Million (2025-2030)
  • Table 130. Brazil Krabbe Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 131. Argentina Krabbe Disease Treatment, by Type USD Million (2025-2030)
  • Table 132. Argentina Krabbe Disease Treatment, by Diagnosed Test USD Million (2025-2030)
  • Table 133. Argentina Krabbe Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 134. Rest of South America Krabbe Disease Treatment, by Type USD Million (2025-2030)
  • Table 135. Rest of South America Krabbe Disease Treatment, by Diagnosed Test USD Million (2025-2030)
  • Table 136. Rest of South America Krabbe Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 137. Asia Pacific Krabbe Disease Treatment, by Country USD Million (2025-2030)
  • Table 138. Asia Pacific Krabbe Disease Treatment, by Type USD Million (2025-2030)
  • Table 139. Asia Pacific Krabbe Disease Treatment, by Diagnosed Test USD Million (2025-2030)
  • Table 140. Asia Pacific Krabbe Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 141. China Krabbe Disease Treatment, by Type USD Million (2025-2030)
  • Table 142. China Krabbe Disease Treatment, by Diagnosed Test USD Million (2025-2030)
  • Table 143. China Krabbe Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 144. Japan Krabbe Disease Treatment, by Type USD Million (2025-2030)
  • Table 145. Japan Krabbe Disease Treatment, by Diagnosed Test USD Million (2025-2030)
  • Table 146. Japan Krabbe Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 147. India Krabbe Disease Treatment, by Type USD Million (2025-2030)
  • Table 148. India Krabbe Disease Treatment, by Diagnosed Test USD Million (2025-2030)
  • Table 149. India Krabbe Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 150. South Korea Krabbe Disease Treatment, by Type USD Million (2025-2030)
  • Table 151. South Korea Krabbe Disease Treatment, by Diagnosed Test USD Million (2025-2030)
  • Table 152. South Korea Krabbe Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 153. Taiwan Krabbe Disease Treatment, by Type USD Million (2025-2030)
  • Table 154. Taiwan Krabbe Disease Treatment, by Diagnosed Test USD Million (2025-2030)
  • Table 155. Taiwan Krabbe Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 156. Australia Krabbe Disease Treatment, by Type USD Million (2025-2030)
  • Table 157. Australia Krabbe Disease Treatment, by Diagnosed Test USD Million (2025-2030)
  • Table 158. Australia Krabbe Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 159. Rest of Asia-Pacific Krabbe Disease Treatment, by Type USD Million (2025-2030)
  • Table 160. Rest of Asia-Pacific Krabbe Disease Treatment, by Diagnosed Test USD Million (2025-2030)
  • Table 161. Rest of Asia-Pacific Krabbe Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 162. Europe Krabbe Disease Treatment, by Country USD Million (2025-2030)
  • Table 163. Europe Krabbe Disease Treatment, by Type USD Million (2025-2030)
  • Table 164. Europe Krabbe Disease Treatment, by Diagnosed Test USD Million (2025-2030)
  • Table 165. Europe Krabbe Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 166. Germany Krabbe Disease Treatment, by Type USD Million (2025-2030)
  • Table 167. Germany Krabbe Disease Treatment, by Diagnosed Test USD Million (2025-2030)
  • Table 168. Germany Krabbe Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 169. France Krabbe Disease Treatment, by Type USD Million (2025-2030)
  • Table 170. France Krabbe Disease Treatment, by Diagnosed Test USD Million (2025-2030)
  • Table 171. France Krabbe Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 172. Italy Krabbe Disease Treatment, by Type USD Million (2025-2030)
  • Table 173. Italy Krabbe Disease Treatment, by Diagnosed Test USD Million (2025-2030)
  • Table 174. Italy Krabbe Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 175. United Kingdom Krabbe Disease Treatment, by Type USD Million (2025-2030)
  • Table 176. United Kingdom Krabbe Disease Treatment, by Diagnosed Test USD Million (2025-2030)
  • Table 177. United Kingdom Krabbe Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 178. Netherlands Krabbe Disease Treatment, by Type USD Million (2025-2030)
  • Table 179. Netherlands Krabbe Disease Treatment, by Diagnosed Test USD Million (2025-2030)
  • Table 180. Netherlands Krabbe Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 181. Rest of Europe Krabbe Disease Treatment, by Type USD Million (2025-2030)
  • Table 182. Rest of Europe Krabbe Disease Treatment, by Diagnosed Test USD Million (2025-2030)
  • Table 183. Rest of Europe Krabbe Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 184. MEA Krabbe Disease Treatment, by Country USD Million (2025-2030)
  • Table 185. MEA Krabbe Disease Treatment, by Type USD Million (2025-2030)
  • Table 186. MEA Krabbe Disease Treatment, by Diagnosed Test USD Million (2025-2030)
  • Table 187. MEA Krabbe Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 188. Middle East Krabbe Disease Treatment, by Type USD Million (2025-2030)
  • Table 189. Middle East Krabbe Disease Treatment, by Diagnosed Test USD Million (2025-2030)
  • Table 190. Middle East Krabbe Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 191. Africa Krabbe Disease Treatment, by Type USD Million (2025-2030)
  • Table 192. Africa Krabbe Disease Treatment, by Diagnosed Test USD Million (2025-2030)
  • Table 193. Africa Krabbe Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 194. North America Krabbe Disease Treatment, by Country USD Million (2025-2030)
  • Table 195. North America Krabbe Disease Treatment, by Type USD Million (2025-2030)
  • Table 196. North America Krabbe Disease Treatment, by Diagnosed Test USD Million (2025-2030)
  • Table 197. North America Krabbe Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 198. United States Krabbe Disease Treatment, by Type USD Million (2025-2030)
  • Table 199. United States Krabbe Disease Treatment, by Diagnosed Test USD Million (2025-2030)
  • Table 200. United States Krabbe Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 201. Canada Krabbe Disease Treatment, by Type USD Million (2025-2030)
  • Table 202. Canada Krabbe Disease Treatment, by Diagnosed Test USD Million (2025-2030)
  • Table 203. Canada Krabbe Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 204. Mexico Krabbe Disease Treatment, by Type USD Million (2025-2030)
  • Table 205. Mexico Krabbe Disease Treatment, by Diagnosed Test USD Million (2025-2030)
  • Table 206. Mexico Krabbe Disease Treatment, by Symptoms USD Million (2025-2030)
  • Table 207. Research Programs/Design for This Report
  • Table 208. Key Data Information from Secondary Sources
  • Table 209. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Krabbe Disease Treatment: by Type USD Million (2018-2023)
  • Figure 5. Global Krabbe Disease Treatment: by Diagnosed Test USD Million (2018-2023)
  • Figure 6. Global Krabbe Disease Treatment: by Symptoms USD Million (2018-2023)
  • Figure 7. South America Krabbe Disease Treatment Share (%), by Country
  • Figure 8. Asia Pacific Krabbe Disease Treatment Share (%), by Country
  • Figure 9. Europe Krabbe Disease Treatment Share (%), by Country
  • Figure 10. MEA Krabbe Disease Treatment Share (%), by Country
  • Figure 11. North America Krabbe Disease Treatment Share (%), by Country
  • Figure 12. Global Krabbe Disease Treatment share by Players 2023 (%)
  • Figure 13. Global Krabbe Disease Treatment share by Players (Top 3) 2023(%)
  • Figure 14. Global Krabbe Disease Treatment share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Polpharma (Poland) Revenue, Net Income and Gross profit
  • Figure 17. Polpharma (Poland) Revenue: by Geography 2023
  • Figure 18. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 19. Sanofi S.A. (France) Revenue: by Geography 2023
  • Figure 20. Takeda Pharmaceutical Company Limited (Japan) Revenue, Net Income and Gross profit
  • Figure 21. Takeda Pharmaceutical Company Limited (Japan) Revenue: by Geography 2023
  • Figure 22. Teva Pharmaceutical Industries Ltd., (Israel) Revenue, Net Income and Gross profit
  • Figure 23. Teva Pharmaceutical Industries Ltd., (Israel) Revenue: by Geography 2023
  • Figure 24. UCB Pharmaceuticals (Belgium) Revenue, Net Income and Gross profit
  • Figure 25. UCB Pharmaceuticals (Belgium) Revenue: by Geography 2023
  • Figure 26. Zhejiang Jiuzhou Pharmaceuticals Co Ltd (China) Revenue, Net Income and Gross profit
  • Figure 27. Zhejiang Jiuzhou Pharmaceuticals Co Ltd (China) Revenue: by Geography 2023
  • Figure 28. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 29. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 30. GlaxoSmithKline Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 31. GlaxoSmithKline Plc (United Kingdom) Revenue: by Geography 2023
  • Figure 32. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 33. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 34. Johnson & Johnson Services Inc (United States) Revenue, Net Income and Gross profit
  • Figure 35. Johnson & Johnson Services Inc (United States) Revenue: by Geography 2023
  • Figure 36. Global Krabbe Disease Treatment: by Type USD Million (2025-2030)
  • Figure 37. Global Krabbe Disease Treatment: by Diagnosed Test USD Million (2025-2030)
  • Figure 38. Global Krabbe Disease Treatment: by Symptoms USD Million (2025-2030)
  • Figure 39. South America Krabbe Disease Treatment Share (%), by Country
  • Figure 40. Asia Pacific Krabbe Disease Treatment Share (%), by Country
  • Figure 41. Europe Krabbe Disease Treatment Share (%), by Country
  • Figure 42. MEA Krabbe Disease Treatment Share (%), by Country
  • Figure 43. North America Krabbe Disease Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Polpharma (Poland)
  • Sanofi S.A. (France)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Teva Pharmaceutical Industries Ltd., (Israel)
  • UCB Pharmaceuticals (Belgium)
  • Zhejiang Jiuzhou Pharmaceuticals Co Ltd (China)
  • Abbott Laboratories (United States)
  • GlaxoSmithKline Plc (United Kingdom)
  • Novartis AG (Switzerland)
  • Johnson & Johnson Services Inc (United States)
Additional players considered in the study are as follows:
Pfizer (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 201 Pages 90 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Krabbe Disease Treatment Market Quantitative research analysis
Global Krabbe Disease Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Polpharma (Poland), Sanofi S.A. (France), Takeda Pharmaceutical Company Limited (Japan), Teva Pharmaceutical Industries Ltd., (Israel), UCB Pharmaceuticals (Belgium), Zhejiang Jiuzhou Pharmaceuticals Co Ltd (China), Abbott Laboratories (United States), GlaxoSmithKline Plc (United Kingdom), Novartis AG (Switzerland) and Johnson & Johnson Services Inc (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Emergence of Pharmacological Chaperone Therapy" is seen as one of major influencing trends for Krabbe Disease Treatment Market during projected period 2023-2030.
The Krabbe Disease Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Krabbe Disease Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Tendinitis Treatment Comprehensive Study by Type (Medication (Pain Relievers, Corticosteroids, Platelet-rich plasma (PRP)), Physical Therapy, Surgery, Other Procedures (Dry needling, Ultrasonic treat...
$ 3750
Duodenal Cancer Comprehensive Study by Type (Adenocarcinoma, Sarcoma, Neuroendocrine Tumors, Lymphoma), Treatment (Surgery, Radiotherapy, Chemotherapy), Diagnosis (Colonoscopy, Capsule Endoscopy, Bar...
$ 3350
Epstein-Barr Virus Infections Treatment Comprehensive Study by Type (Apatinib Mesylate, AR-12, Baltaleucel-T, Others), Application (Hospital, Clinic, Ambulatory Surgery Centers, Others) Players and R...
$ 3500
Myelodysplastic Drugs Comprehensive Study by Type (MDS with single lineage dysplasia, MDS with ring Sider oblasts, MDS with multilineage dysplasia's, MDS with excess blasts, Myelodysplastic syndrome ...
$ 3500
Pyelonephritis Comprehensive Study by Type (Finafloxacin, Fosfomycin Tromethamine, Nacubactam, Plazomicin Sulfate), Application (Hospitals, Clinics), Treatement (Antibiotics, Hospital Admission, Surg...
$ 3500
Cerebral Palsy Treatment Comprehensive Study by Type (Medications (Musel or Nerve Injections and Oral Muscle Relaxants), Therapies (Physical Therapy, Occupational Therapy, Speech and Language Therapy...
$ 3750